�The  University  of Miami  Miller  School  of Medicine  and Seed-One  Ventures  announce the formation of Heat  Biologics  Inc.  to develop two related platform technologies which introduce a novel lung cancer vaccine and asthma therapy, with potential drop applications in the treatment of a number of other incitive diseases.  The  two treatments were developed by Eckhard  Podack,  M.D.,  Ph.D.,  Sylvester  Distinguished  Professor  of Medicine  and chairman of the Department  of Microbiology  and Immunology.   
Seed-One  Ventures  forms new companies based on cutting-edge technologies and discovery medical therapies. 
This  collaboration is the work of UM  Innovation,  the University  of Miami's  home of technology progress which develops university-generated treatments or devices, and whole kit and caboodle with businesses to take that engineering into the marketplace.  Under  the umbrella of UM  Innovation,  the Wallace  H.  Coulter  Center  for Translational  Research  produced the lung cancer vaccine, which is currently in Phase  1 clinical trials, and afterward matched both groundbreaking treatments with Seed-One  Ventures.  
"Seed-One  Ventures  evaluates hundreds of technologies every year, and the treatments developed by Dr.  Podack  are among the best we've seen," said Jeffrey  Wolf,  managing partner, Seed-One  Ventures.   "His  approach represents a prototype shift, a non-traditional sentiment of certain prevailing ideas about immunology. The  conclusion to contour Heat  Biologics  around Dr.  Podack's  breakthrough work was an easy one." 
Bart  Chernow,  MD,  vice provost for technology advancement at the Miller  School,  indicated how proud of he was that Mr.  Wolf  and his colleagues at Heat  Biologics  would be helping in the research and development of this significant therapeutic attack.  "The  formation of this spin cancelled company will hopefully enable Dr.  Podack's  discovery to reach its full potency, and if it is found to be safe and efficacious, it volition help many people suffering from lung cancer." 
Dr.  Podack's  novel lung cancer vaccine, gp-96, was highly-developed to treat non-small cell lung malignant neoplastic disease (NSCLC),  which accounts for 85 percentage of all lung cancers.  For  NSCLC  patients, surgery and chemotherapy are often the only options, so this treatment will replete a significant need. 
 While  conventional vaccines are secondhand to forestall infectious diseases, Dr.  Podack's  treatment is meant to stimulate the immune system to fight the disease once it is diagnosed.  The  body's immune organisation does not recognize NSCLC  as unsafe, so it does non attack those cells.  To  trigger the immune system, Dr.  Podack  began working with gp-96, a heat energy shock protein.  Normally,  this heat shock protein cadaver in the cell and is protected from the immune system.  Dr.  Podack  genetically engineered a NSCLC  cell to secrete this protein, which "induces tumor-antigen specific cytotoxic T  cells and natural killer cells," he explains.  
 This  is where the second of the deuce complementary technologies comes into play.  Vaccines  against cancer have been limited in effectiveness by regulatory T  cells, which block the immune response system.  Dr.  Podack  has developed tumor necrosis gene receptor (TNFR)  25 agonists and antagonists, which tooshie be used to benefit patients in two ways.  TNFR25  agonists have the ability to block the production of regulatory T  cells, allowing the immune system to work uninhibited.  By  applying this therapy in conjunction with the gp-96 vaccine, the antineoplastic treatment tooshie be much more effective.  Dr.  Podack  notes that it is five to ten times more in force in mice.  He  sees a lot of hope with this new therapy.  "The  gp96-vaccine in combination with TNFR25  agonists offers the best hope to conquer crab and other intractable diseases." 
TNFR25  antagonists offer hope to those with bronchial asthma and other inflammatory diseases.  As  the opposite of TNFR25  agonists, this antibody works as an anti-inflammatory drug agent, easement the symptoms of asthma attack and several other autoimmune diseases. 
 Heat  Biologics  and the University  of Miami  are presently enrolling patients in a Phase  I  clinical trial of gp-96, under the direction of Luis  E.  Raez,  M.D.,  associate professor of music and co-leader of the Lung  Cancer  Site  Disease  Group  at UM/Sylvester  Comprehensive  Cancer  Center.   A  Phase  I  trial is meant to determine the safety of a treatment.  Dr.  Podack  believes this vaccinum could get a fast track for review by the U.S.  Food  and Drug  Administration  because there are so few effective treatments for NSCLC.   A  fast-track appellative would base a six-month review following a Phase  III  tribulation involving hundreds of patients. 
Heat  Biologics  is i of respective cutting-edge health care technology and biotechnology companies founded in Florida  by Seed-One  in recent age, making it one of the region's more active seed-stage venture firms. Seed-One  builds its portfolio companies from the ground up and actively manages each. Mr.  Wolf  will service as CEO  of Heat  Biologics  and oversee the development and commercialization of the company's platform technologies. 
About  UM  InnovationUM  Innovation  is the home of technology progress at the University  of Miami  and serves to nurture and integrate UM's  vibrant and comprehensive research initiatives. UM  Innovation  incorporates the Office  of Technology  Transfer,  the Wallace  H.  Coulter  Center  for Translational  Research  and the young Life  Science  Park  and serves as a bridge between staff scientists seeking to commercially transfer their research efforts and incorporated entities concerned in accessing and forward innovative technologies. 
About  Seed-One  VenturesSeed-One  Ventures,  LLC,  is focused on forming new companies from the ground up based upon find technologies with significant commercial applications. Seed-One  actively manages each new venture it creates.   Seed-One's  target areas for young venture creation include bioengineering, pharmaceuticals, information systems, and hardware and software technologies. 
University  of Miami  Miller  School  of Medicine
More  info